2023
CRP Versus SAA for Identification of Inflammatory Hepatic Adenomas
Soon G, Yasir S, Jain D, Kakar S, Wu T, Yeh M, Torbenson M, Chen Z. CRP Versus SAA for Identification of Inflammatory Hepatic Adenomas. Applied Immunohistochemistry & Molecular Morphology 2023, 31: 590-595. PMID: 37698958, DOI: 10.1097/pai.0000000000001155.Peer-Reviewed Original ResearchConceptsC-reactive proteinFocal nodular hyperplasiaHepatic adenomaInflammatory hepatic adenomaInflammatory adenomasNodular hyperplasiaH-scorePositive C-reactive proteinBeta-catenin activationProportion of casesInflammatory hepatocellular adenomaGlutamine synthetase stainingComplication riskRetrospective studyResection specimensPatient managementHepatocellular adenomaImmunohistochemical stainingSerum amyloidPositive stainingControl groupAdenomasIntense stainingMolecular classificationCRP staining
2022
An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center.
Wang JD, Sebastian C, Walther Z, Suresh T, Lacy J, Zhang X, Jain D. An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center. Archives Of Pathology & Laboratory Medicine 2022, 147: 185-192. PMID: 35512224, DOI: 10.5858/arpa.2021-0457-oa.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Squamous CellColoring AgentsHumansLiver NeoplasmsNeoplasms, Unknown PrimaryTertiary HealthcareConceptsLiver biopsyUnknown primaryIHC markersPrimary siteTrue carcinomaTertiary care medical centerAvailable clinicopathologic dataSquamous cell carcinomaClinicopathologic dataHepatic metastasesNonepithelial tumorsCell carcinomaInstitutional databaseClinical managementStain usePractice patternsNeuroendocrine neoplasmsImmunohistochemical markersMedical CenterMorphologic patternsIndividualized approachCarcinomaBiopsyMetastasisTumors
2021
Inhibin-positive hepatic carcinoma: proposal for a solid-tubulocystic variant of intrahepatic cholangiocarcinoma
Wen KW, Joseph NM, Srivastava A, Saunders TA, Jain D, Rank J, Feely M, Zarrinpar A, Al Diffalha S, Shyn PB, Graham RP, Drage MG, Kakar S. Inhibin-positive hepatic carcinoma: proposal for a solid-tubulocystic variant of intrahepatic cholangiocarcinoma. Human Pathology 2021, 116: 82-93. PMID: 34298064, DOI: 10.1016/j.humpath.2021.07.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultBile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaFemaleHumansInhibinsLiver NeoplasmsConceptsSex cord-stromal tumorsCapture-based next-generation sequencingIntrahepatic cholangiocarcinomaNext-generation sequencingSolitary large massPrimary liver carcinomaPrimary liver neoplasmRecurrent genetic abnormalitiesThyroid follicular tumorsAggressive courseRecurrent genomic changesCystic areasImmunophenotypic featuresRare tumorThyroid originCytologic atypiaLiver neoplasmsHepatocellular carcinomaPatchy stainingHepatic carcinomaLiver carcinomaMorphologic patternsHepatocellular differentiationFollicular tumorsSmall seriesPediatric Hepatocellular Adenomas
Pacheco MC, Torbenson MS, Wu TT, Kakar S, Jain D, Yeh MM. Pediatric Hepatocellular Adenomas. The American Journal Of Surgical Pathology 2021, 45: 1641-1647. PMID: 34148984, PMCID: PMC8608351, DOI: 10.1097/pas.0000000000001763.Peer-Reviewed Original ResearchConceptsHepatocellular adenomaPrepubescent groupPediatric patientsNonsyndromic groupΒ-cateninAdenoma subtypesImmunohistochemical staining profileHepatocellular adenoma subtypesPostpubescent groupClinical characteristicsUnclassified subtypeClinical historySyndromic groupsImmunohistochemical stainingPatientsType adenomasAdenomasSyndromeAge groupsLarger studyStaining profileSubtypesGreater percentageGroupLanguage searchHNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA, Taddei T, Jain D, Zhang X. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas. Archives Of Pathology & Laboratory Medicine 2021, 146: 220-226. PMID: 34086854, DOI: 10.5858/arpa.2020-0725-oa.Peer-Reviewed Original Researchα-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study
Lu SX, Huang YH, Liu LL, Zhang CZ, Yang X, Yang YZ, Shao CK, Li JM, Xie D, Zhang X, Jain D, Yun JP. α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study. British Journal Of Cancer 2021, 124: 1988-1996. PMID: 33824478, PMCID: PMC8184895, DOI: 10.1038/s41416-021-01363-4.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaHepatocytic lesionsDiagnosis of HCCLiver biopsy cohortHepatocyte paraffin 1Independent retrospective cohortsBenign liver lesionsMulti-center studyGood diagnostic valueNovel diagnostic biomarkersArginase-1 (Arg-1) proteinsΑ-fetoprotein mRNASurgical cohortRetrospective cohortBiopsy cohortHepPar-1Arg-1Liver lesionsDiagnostic biomarkersDiagnostic valueMalignancy lesionsLesionsGlypican3CohortSpecific markers
2019
Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma
Balitzer D, Joseph NM, Ferrell L, Shafizadeh N, Jain D, Zhang X, Yeh M, di Tommaso L, Kakar S. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Modern Pathology 2019, 32: 1486-1494. PMID: 31186529, DOI: 10.1038/s41379-019-0290-0.Peer-Reviewed Original ResearchConceptsCholangiolocellular carcinomaIntrahepatic cholangiocarcinomaLow-grade cytologic atypiaPrimary liver carcinomaCapture-based next-generation sequencingCanals of HeringNumber alterationsHistologic subtypeCarcinoma componentCytologic atypiaImmunohistochemistry resultsCholangiocarcinomaLiver carcinomaCarcinomaSelect intronsCell subtypesStem cell subtypesHepatocellular componentDistinct entityMutational profileSubtypesNext-generation sequencingCD56Genomic profilesCD117Proinsulin Expressing Neuroendocrine Tumors of the Pancreas
Celli R, Tang LH, Cai G, Freedman-Weiss M, Colunga M, Salem RR, Majumdar S, Jain D. Proinsulin Expressing Neuroendocrine Tumors of the Pancreas. Pancreas 2019, 48: 55-59. PMID: 30451800, DOI: 10.1097/mpa.0000000000001196.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsAvailable clinicopathologic dataIHC-negative tumorsSurgical oncology centersNormal insulin levelsIHC-positive tumorsSerum proinsulinClinicopathologic featuresPNET patientsClinicopathologic dataHypoglycemic patientsInsulin levelsProspective studyOncology centersSerum glucoseSuch tumorsClinical significanceInsulin immunohistochemistryRare casePatientsImmunohistochemistryProinsulinomaTumorsInsulinoma
2018
A practical diagnostic approach to hepatic masses.
Vyas M, Jain D. A practical diagnostic approach to hepatic masses. Indian Journal Of Pathology And Microbiology 2018, 61: 2-17. PMID: 29567877, DOI: 10.4103/ijpm.ijpm_578_17.Peer-Reviewed Original ResearchConceptsDifferential diagnosisHepatic massCorrect diagnosisRight diagnosisBackground liver diseaseUnknown primary siteFocal nodular hyperplasiaHepatic mass lesionsPractical diagnostic approachList of antibodiesNonhepatocellular originProper workupClinical presentationHepatocellular originLiver diseaseHistologic featuresPrimary lesionClinicopathological correlationHepatic adenomaVascular tumorsMass lesionNonepithelial neoplasmsCommon siteNeedle biopsyNodular hyperplasia
2017
A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors
Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors. Journal Of Gastrointestinal Surgery 2017, 21: 1335-1341. PMID: 28510792, DOI: 10.1007/s11605-017-3428-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAgedBiomarkers, TumorFemaleHumansInsulinomaMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsProinsulinConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsSystematic reviewRare pancreatic neuroendocrine tumorYale-New Haven HospitalMajority of patientsMedian tumor diameterLower insulin levelsBiomedical databases PubMedNew Haven HospitalSymptomatic hypoglycemiaMost patientsFemale predominanceTumor diameterClinicopathologic featuresInsulin levelsUncommon diseaseMean ageOvid MEDLINEHormonal levelsDatabases PubMedPatientsProinsulinomaHormone productionTumors
2016
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives Of Pathology & Laboratory Medicine 2016, 140: 1345-1363. PMID: 27841667, DOI: 10.5858/arpa.2016-0331-cp.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorClinical Decision-MakingCombined Modality TherapyDecision TreesDiagnosis, DifferentialEsophageal NeoplasmsEvidence-Based MedicineHumansMedical OncologyMolecular Diagnostic TechniquesMolecular Targeted TherapyMutationNeoplasm GradingNeoplasm StagingPathology, ClinicalReceptor, ErbB-2Societies, MedicalStomach NeoplasmsSystematic Reviews as TopicUnited StatesConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapyHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal Of Clinical Oncology 2016, 35: 446-464. PMID: 28129524, DOI: 10.1200/jco.2016.69.4836.Peer-Reviewed Original ResearchConceptsAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaEvidence-based guidelinesAssessment of HER2Clinical OncologyAmerican SocietyClinical decisionClinical pathologyAmerican PathologistsAccuracy of HER2Initial therapyMorphologic selectionOptimal HER2Combination chemotherapyHER2 statusOnly biomarkerSpecific therapyHER2 testingTumor specimensPatientsHER2Systematic reviewClinical implicationsNeoplastic tissueTherapy
2015
Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma
Nguyen T, Phillips D, Jain D, Torbenson M, Wu TT, Yeh MM, Kakar S. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma. Archives Of Pathology & Laboratory Medicine 2015, 139: 1028-34. PMID: 26230595, DOI: 10.5858/arpa.2014-0479-oa.Peer-Reviewed Original ResearchConceptsHep Par 1Polyclonal carcinoembryonic antigenArginase-1Hepatocellular carcinomaGlypican-3Carcinoembryonic antigenPAR-1Immunohistochemical markersSensitive markerHepatocellular differentiationLiver biopsyCarcinomaBest overall sensitivityHepatocellular markersLimited tissueAntigen 1Overall sensitivityDiagnosisCombined useReliable diagnosisPositive resultsMarkersLimited roleImmunohistochemical pitfalls in the diagnosis of hepatocellular adenomas and focal nodular hyperplasia: accurate understanding of diverse staining patterns is essential for diagnosis and risk assessment
Kakar S, Torbenson M, Jain D, Wu TT, Yeh M, Ferrell LD. Immunohistochemical pitfalls in the diagnosis of hepatocellular adenomas and focal nodular hyperplasia: accurate understanding of diverse staining patterns is essential for diagnosis and risk assessment. Modern Pathology 2015, 28: 159-160. PMID: 25560413, DOI: 10.1038/modpathol.2014.121.Peer-Reviewed Original Research
2013
Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma
Joseph NM, Ferrell LD, Jain D, Torbenson MS, Wu TT, Yeh MM, Kakar S. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Modern Pathology 2013, 27: 62-72. PMID: 23807780, DOI: 10.1038/modpathol.2013.114.Peer-Reviewed Original ResearchMeSH KeywordsAdenoma, Liver CellAdolescentAdultAgedBiomarkers, TumorBiopsyChildChild, PreschoolC-Reactive ProteinDiagnosis, DifferentialDiagnostic ErrorsFemaleFocal Nodular HyperplasiaGlutamate-Ammonia LigaseHumansImmunohistochemistryInflammation MediatorsLiver NeoplasmsMaleMiddle AgedPredictive Value of TestsSerum Amyloid A ProteinYoung AdultConceptsSerum amyloid-associated proteinFocal nodular hyperplasiaAmyloid-associated proteinsInflammatory hepatocellular adenomaNodular hyperplasiaHepatocellular adenomaStaining patternDuctular reactionFibrous stromaFocal nodular hyperplasia casesMap-like patternOverlapping histological featuresGlutamine synthetase stainingHistological featuresProtein immunohistochemistryHyperplasia casesIndeterminate lesionsPositive stainingHyperplasiaDiagnostic utilityAdenomasBlood vesselsFrequent overlapStainingDiagnostic errorsImmunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma
Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M, Kakar S. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Modern Pathology 2013, 26: 782-791. PMID: 23348905, DOI: 10.1038/modpathol.2012.243.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, ScirrhousAdultAgedArginaseBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorCarcinoma, HepatocellularChi-Square DistributionCholangiocarcinomaDiagnosis, DifferentialDiagnostic ErrorsFemaleGlypicansHumansImmunohistochemistryLiver NeoplasmsMaleMiddle AgedPredictive Value of TestsReproducibility of ResultsConceptsScirrhous hepatocellular carcinomaClassical hepatocellular carcinomaHepatocellular carcinomaHepatocellular carcinoma casesGlypican-3Carcinoma casesMarked stromal fibrosisEpithelial cell adhesion moleculeMetastatic adenocarcinomaIntrahepatic cholangiocarcinomaStromal fibrosisCytokeratin 7Needle biopsyFrequent positivityCell adhesion moleculeHepPar-1Immunohistochemical pitfallsMorphological subtypesCarcinomaAdenocarcinomaHepatocellular differentiationCytokeratin 19Erroneous diagnosisReliable markerAdhesion molecules
2012
PDX-1, CDX-2, TTF-1, and CK7
Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF-1, and CK7. The American Journal Of Surgical Pathology 2012, 36: 737-743. PMID: 22498824, DOI: 10.1097/pas.0b013e31824aba59.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCDX2 Transcription FactorDiagnosis, DifferentialDNA-Binding ProteinsFemaleHomeodomain ProteinsHumansImmunohistochemistryIntestinal NeoplasmsKeratin-20Keratin-7Liver NeoplasmsLung NeoplasmsMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsSensitivity and SpecificitySingle-Blind MethodTrans-ActivatorsTranscription FactorsConceptsGI neuroendocrine tumorsThyroid transcription factor-1Pancreatic neuroendocrine tumorsBronchopulmonary neuroendocrine tumorsMetastatic neuroendocrine tumorsPrimary neuroendocrine tumorNeuroendocrine tumorsCDX-2PDX-1Primary siteMetastatic pancreatic neuroendocrine tumorsPrimary pancreatic neuroendocrine tumorsDuodenal neuroendocrine tumorsΒ-cell functionSimilar morphologic featuresPancreatic duodenal homeobox-1Good overall diagnostic accuracyOverall diagnostic accuracyDuodenal homeobox 1Radiologic dataTranscription factor 1IHC panelImmunohistochemical markersIHC analysisKeratin 7
2009
Molecular markers and death from prostate cancer.
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals Of Internal Medicine 2009, 150: 595-603. PMID: 19414838, DOI: 10.7326/0003-4819-150-9-200905050-00005.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelProstate cancerLong-term riskAntigen levelsMicrovessel densityMedian prostate-specific antigen levelIncreased long-term riskVeterans Affairs Healthcare SystemIncident prostate cancerObservational cohort studyProportional hazards analysisTime of diagnosisHigher microvessel densityVeterans Health AdministrationBcl-2Years of ageProstate cancer biopsiesClinical care recordsClinical characteristicsCohort studyPatient ageMedian ageComorbid conditionsHistologic gradeResidual confoundingDiagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma
Ahmad I, Iyer A, Marginean CE, Yeh MM, Ferrell L, Qin L, Bifulco CB, Jain D. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma. Human Pathology 2009, 40: 726-734. PMID: 19157505, DOI: 10.1016/j.humpath.2008.10.018.Peer-Reviewed Original ResearchConceptsTelangiectatic focal nodular hyperplasiaFocal nodular hyperplasia casesFocal nodular hyperplasiaNeuronal cell adhesion moleculeHepatic adenomaNodular hyperplasiaCytokeratin 7Cytokeratin 19Hyperplasia casesNeedle biopsyCell adhesion moleculeBile ductAdhesion moleculesCD34 stainCytokeratin 7 stainingCorresponding resection specimensDiagnostic useParaffin-embedded sectionsDistinct staining patternsProspective studyResected specimensHistologic featuresResection specimenResection specimensCorresponding resections
2008
Identification of lymphatics within the colonic lamina propria in inflammation and neoplasia using the monoclonal antibody D2-40.
Kenney BC, Jain D. Identification of lymphatics within the colonic lamina propria in inflammation and neoplasia using the monoclonal antibody D2-40. The Yale Journal Of Biology And Medicine 2008, 81: 103-13. PMID: 18827885, PMCID: PMC2553648.Peer-Reviewed Original Research